SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE)--Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today reported the topline results from a Phase 2 clinical trial evaluating the safety and efficacy of an antiviral teslexivir 5% gel dosed topically twice daily in 218 subjects for the treatment of condyloma, or anogenital warts.
The primary efficacy endpoint was defined as complete clearance of baseline condyloma by week 16.Vaxart Reports Topline Results from Phase 2 Trial of Teslexivir™
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться